NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease

American Journal of Gastroenterology

Volumn 103, Issue 5, 2008, Pages 1197-1202

  Angelberger, Sieglinde ^a   Reinisch, Walter ^a   Dejaco, Clemens ^a   Miehsler, Wolfgang ^a   Waldhoer, Thomas ^a   Wehkamp, Jan ^b   Lichtenberger, Cornelia ^a   Schaeffeler, Elke ^b   Vogelsang, Harald ^a   Schwab, Matthias ^b   Teml, Alexander ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA DEFENSIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ANTIBIOTIC THERAPY; ANUS FISTULA; ARTICLE; CROHN DISEASE; DIARRHEA; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ALLELES; ANTI-INFECTIVE AGENTS; BETA-DEFENSINS; CIPROFLOXACIN; CROHN DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; RECTAL FISTULA; TREATMENT FAILURE;

EID: 43549101139     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01741.x     Document Type: Article

References (45)

1. Lockhart-Mummery HE. Symposium. Crohn's disease: Anal lesions. Dis Colon Rectum 1975 18 : 200 2.
2. Schwartz DA, Herdman CR. Review article: The medical treatment of Crohn's perianal fistulas. Aliment Pharmacol Ther 2004 19 : 953 67.
3. Hellers G, Bergstrand O, Ewerth S, et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut 1980 21 : 525 7.
4. Schwartz DA, Loftus EV Jr., Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 2002 122 : 875 80.
5. Williams DR, Coller JA, Corman ML, et al. Anal complications in Crohn's disease. Dis Colon Rectum 1981 24 : 22 4.
6. Caprilli R, Gassull MA, Escher JC, et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: Special situations. Gut 2006 55 (Suppl 1 I36 58.
7. Dejaco C, Harrer M, Waldhoer T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003 18 : 1113 20.
8. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 1982 83 : 383 7.
9. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984 79 : 533 40.
10. Turunen U, Farkkila M, Valtonen V. Long-term outcome of ciprofloxacine treatment in severe perianal or fistulous Crohn's disease [abstract]. Gastroenterology 1993 104 : A793.
11. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med 2001 135 : 906 18.
12. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 411 : 599 603.
13. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411 : 603 6.
14. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005 19 (Suppl A 5 36.
15. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003 278 : 5509 12.
16. Girardin SE, Boneca IG, Viala J, et al. NOD2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003 278 : 8869 72.
17. Abraham C, Cho JH. Functional consequences of NOD2 (CARD15) mutations. Inflamm Bowel Dis 2006 12 : 641 50.
18. Wehkamp J, Salzman NH, Porter E, et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005 102 : 18129 34.
19. Wehkamp J, Harder J, Weichenthal M, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha defensin expression. Gut 2004 53 : 1658 64.
20. Wehkamp J, Fellermann K, Herrlinger KR, et al. Mechanisms of disease: Defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005 2 : 406 15.
21. Wehkamp J, Fellermann K, Herrlinger KR, et al. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002 14 : 745 52.
22. Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003 73 : 591 600.
23. Fellermann K, Stange DE, Schaeffeler E, et al. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn's disease of the colon. Am J Hum Genet 2006 79 : 439 48.
24. Stange EF, Travis SP, Vermeire S, et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gut 2006 55 (Suppl 1 I1 15.
25. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: A long-term, randomized double-blind study. N Engl J Med 1980 302 : 981 7.
26. Korelitz BI, Present DH. Favorable effect of 6-MP on fistulae of Crohn's disease. Dig Dis Sci 1985 30 : 58 64.
27. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 405.
28. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: A cohort study. Lancet 2002 359 : 1661 5.
29. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmakol 2004 369 : 23 37.
30. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 : 383 91.
31. Thomas DC, Witte JS. Point: Population stratification: A problem for case-control studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev 2002 11 : 505 12.
32. Daly AK. Candidate gene case-control studies. Pharmacogenomics 2003 4 : 127 39.
33. Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004 14 : 523 5.
34. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002 122 : 512 30.
35. Janowitz HD, Croen EC, Sachar DB. The role of the fecal stream in Crohn's disease: A historical and analytic review. Inflamm Bowel Dis 1998 4 : 29 39.
36. Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn's disease. World J Surg 2000 24 : 1258 62 discussion 1262-3.
37. Singh B, McC Mortensen NJ, Jewell DP, et al. Perianal Crohn's disease. Br J Surg 2004 91 : 801 14.
38. Sandborn WJ, Present HD, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: A randomized, placebo-controlled trial. Gastroenterology 2003 125 : 380 8.
39. Kobayashi KS, Chamaillard M, Ogura Y, et al. NOD2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005 307 : 731 4.
40. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999 286 : 113 7.
41. Salzman NH, Ghosh D, Huttner KM, et al. Protection against enteric salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003 422 : 522 6.
42. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998 115 : 1405 13.
43. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002 122 : 44 54.
44. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004 127 : 412 21.
45. Tamboli CP, Neut C, Desreumaux P, et al. Dysbiosis in inflammatory bowel disease. Gut 2004 53 : 1 4.